Iris M Seignette

6PUBLICATIONS
67CO-AUTHORS
Predictive and prognostic markersHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 17, 2026
Pre-existing immunity and hrHPV status determine immunotherapy response in advanced penile cancer: biomarkers and overall survival in the PERICLES trial.

|Nov 19, 2025
Tumour-reactive heterotypic CD8 T cell clusters from clinical samples.

Sofía Ibáñez-Molero, Johanna Veldman, Juan Simon Nieto

|Jun 09, 2025
Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study.

Chantal F Stockem, Alberto Gil-Jimenez, Hamza Ali

|Apr 14, 2025
Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial.

S L Aronson, B Thijssen, M Lopez-Yurda

|Jul 24, 2024
Platinum-Based Chemotherapy Induces Opposing Effects on Immunotherapy Response-Related Spatial and Stromal Biomarkers in the Bladder Cancer Microenvironment.

Maksim A Chelushkin, Jeroen van Dorp, Sandra van Wilpe

|Jul 14, 2023
Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features.

Hanne Lefrère, Kat Moore, Giuseppe Floris

Pageof 1

Frequent Collaborators

5 joint publications

Lodewyk Wessels

4 joint publications

Erik Hooijberg

4 joint publications

Annegien Broeks

3 joint publications

Daniel J Vis